Nama's AI scorecard currently rates Insmed Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does INSM report earnings?

Insmed's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.35.

What is the INSM price target?

The median analyst price target from 22 analysts is $195.00, with a range of $158.00 – $243.00.

Is INSM Shariah compliant?

Nama's AAOIFI-style screen reads Insmed as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Insmed (INSM)

Healthcare · Biotechnology · NASDAQ

Insmed (INSM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $25.10B and a free-cash-flow yield of -4.2%. Over the most recent reported fiscal year, revenue grew 66.7%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Trailing · -45.2% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-46.2%

How far the last close sits under the highest price of the past five years.

Market cap	$25.10B
Trailing P/E	—
Price / book	34.6
Price / sales	16.5
FCF yield	-4.2%
Dividend yield	—
Gross margin	84.4%
Operating margin	-41.7%
Net margin	-39.9%
Revenue growth (YoY)	+66.7%
Revenue growth (3-yr annual)	+35.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

INSM earnings

Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.35). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$0.46	-$0.37	-24.3%	$524.43M
Q2 2026	Aug 6, 2026	-$0.06	-$0.68	+91.2%	$425.49M
Q1 2026	May 7, 2026	-$0.76	-$1.00	+24.0%	$305.96M
Q4 2025	Feb 19, 2026	-$1.54	-$1.17	-31.6%	$263.84M

INSM analyst price target

Median target $195.00 from 22 analysts, ranging $158.00 – $243.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live INSM data on Nama Insights →

Recent Congressional trades

Insmed trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 7, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Nov 18, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Oct 10, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Sep 12, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Aug 14, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Jul 16, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	May 14, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 9, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jun 8, 2024

INSM FAQ

Is INSM a buy?: Nama's AI scorecard currently rates Insmed Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does INSM report earnings?: Insmed's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.35.
What is the INSM price target?: The median analyst price target from 22 analysts is $195.00, with a range of $158.00 – $243.00.
Is INSM Shariah compliant?: Nama's AAOIFI-style screen reads Insmed as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.